????? ?? ?? ? ??? ????????????? ????????????????? ???????????????????Unfit individuals also have the choice of venetoclax moreover obinutuzumab (VO) as frontline therapy. This is predicated with a period III trial that in contrast VO with ClbO in aged/unfit people.113 VO was remarkable when it comes to reaction price and development-absolutely free